戴納基 DYN 深滬

等待開盤 09-23 09:30:00 美东时间

13.42

+0.290

+2.21%

華盛通

立即下載

最高13.48
今開13.13
成交量 131.09万股
最低 12.78
昨收 13.13
總市值 19.06亿
52周最高 36.09
市盈率 ^靜 --
換手率 0.92%
52周最低 6.36
委比 -58.59%
總股本 1.42亿
歷史最高 47.45
量比 0.62
振幅 5.33%
歷史最低 4.30
每手 1
風險率 8.78%

個股概要

財務分析

公司資料

分紅派息

分時圖
日k
周k
月k

相關新聞

BioNTech Advances On Positive Phase 3 Breast Cancer Drug Data

BioNTech and DualityBio reported Phase 3 success for trastuzumab pamirtecan in HER2 breast cancer, setting stage for regulatory submission in China.

09-05 21:09
Dynemic Products Limited Announces AGM Details for 2024-25

The latest announcement is out from Dynemic Products Limited ( ($IN:DYNPRO) ). ...

09-01 15:24
Dyne Therapeutics to Present at Upcoming Investor Conferences

Dyne Therapeutics announced that its management will participate in two upcoming investor conferences: the Cantor Global Healthcare Conference 2025 on September 5, 2025, and the Morgan Stanley 23rd Annual Global Healthcare Conference on September 8, 2025, both in New York. Live webcasts of the presentations will be available on the company's website, with replays accessible for 90 days. Dyne Therapeutics focuses on treating genetically driven neu...

08-27 11:30
Raymond James Upgrades Dyne Therapeutics to Strong Buy, Raises Price Target to $35

Raymond James analyst Martin Auster upgrades Dyne Therapeutics (NASDAQ:DYN) from Outperform to Strong Buy and raises the price target from $31 to $35.

08-25 22:47
Dynagas LNG Partners LP Announces Cash Distribution for the Quarter Ended June 30, 2025 of $0.049 Per Unit

<p>Dynagas LNG Partners LP announced a quarterly cash distribution of $0.049 per unit, payable on August 29, 2025, to unit holders of record as of August 25, 2025. The company owns and operates six LNG carriers with a total carrying capacity of 914,000 cubic meters. Additional details, including contact information and forward-looking statements, are provided on the company's website and in the press release.</p>

08-13 20:05
映恩生物的五年，资本很满意。。。

（来源：成长企业常识）后浪森林研究室 | 罗可编辑 | 许佳维映恩生物从2020年创立只有五年时间，布局了12款ADC管线，不仅在快速...

08-11 07:58
市值58亿美元，诺华拟收购Avidity Biosciences

（来源：CHC医疗传媒） 8月6日，据英国《金融时报》援引知情人士的话说，诺华最近几周表示对生物技术公司Avidity Biosciences感兴趣。《金融时报...

08-08 15:00
Dyne gets FDA breakthrough therapy status for DMD therapy

Dyne Therapeutics (NASDAQ:DYN) said that it has received FDA's breakthrough therapy status for its experimental drug DYNE-251, aimed at treating patients with Duchenne muscular dystrophy. The FDA's de...

08-04 20:54
Dyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-251 in Duchenne Muscular Dystrophy (DMD)

Dyne Therapeutics announced that the FDA granted Breakthrough Therapy Designation to DYNE-251 for treating Duchenne muscular dystrophy (DMD) patients amenable to exon 51 skipping, based on data from the ongoing DELIVER trial. DYNE-251 has shown sustained functional improvement and near-full-length dystrophin expression. The company aims to submit a Biologics License Application (BLA) for U.S. accelerated approval in early 2026, following data fro...

08-04 11:30
Stifel Maintains Buy on Dyne Therapeutics, Lowers Price Target to $36

Stifel analyst Paul Matteis maintains Dyne Therapeutics (NASDAQ:DYN) with a Buy and lowers the price target from $66 to $36.

07-31 23:50

派息除權日	每股總股息	派息日期
2002-05-30	0.08	2002-06-17
2002-02-27	0.08	2002-03-15
2001-11-29	0.08	2001-12-17
2001-08-29	0.08	2001-09-17
2001-05-29	0.08	2001-06-15
2001-02-27	0.08	2001-03-15
2000-11-29	0.08	2000-12-15
2000-08-29	0.08	2000-09-15
2000-05-26	0.15	2000-06-15
2000-02-24	0.04	2000-03-31
1999-12-01	0.01	1999-12-21
1999-09-01	0.01	1999-09-21
1999-06-01	0.01	1999-06-28
1999-03-04	0.01	1999-03-26
1998-12-01	0.01	1998-12-21
1998-09-01	0.01	1998-09-21
1998-05-28	0.01	1998-06-22
1998-03-09	0.01	1998-03-27
1997-12-01	0.01	1997-12-19
1997-08-22	0.01	1997-09-16
1997-05-21	0.01	1997-06-16
1997-02-13	0.01	1997-03-05
1996-11-27	0.01	1996-12-16
1996-07-25	0.01	1996-09-03
1996-05-16	0.01	1996-06-04
1996-03-21	0.01	1996-04-09
1995-12-14	0.01	1996-01-02
1995-09-21	0.01	1995-10-10
1995-06-16	0.01	1995-07-05
1995-03-01	0.01	1995-03-21
1994-12-01	0.01	1994-12-21
1994-08-31	0.01	1994-09-21
1994-06-01	0.01	1994-06-21
1994-03-01	0.01	1994-03-21
1984-10-03	0.66	1984-11-01
1984-07-03	0.66	1984-08-01
1984-04-04	0.66	1984-05-01
1984-01-04	0.66	1984-02-01
1983-10-03	0.62	1983-11-01
1983-07-05	0.62	1983-08-01
1983-04-05	0.62	1983-05-02
1983-01-04	0.62	1983-02-01
1982-10-04	0.62	1982-11-01
1982-07-02	0.62	1982-08-02
1982-04-02	0.62	1982-05-01
1982-01-05	0.62	1982-02-01
1981-10-05	0.60	1981-11-02
1981-07-06	0.60	1981-08-01
1981-04-06	0.60	1981-05-01
1981-01-05	0.60	1981-02-02
1980-10-06	0.60	1980-11-01
1980-07-03	0.60	1980-08-01
1980-04-02	0.57	1980-05-01
1980-01-03	0.57	1980-01-31
1979-10-02	0.57	1979-10-31
1979-07-02	0.57	1979-07-31
1979-04-03	0.57	1979-04-30
1979-01-03	0.57	1979-01-31
1978-10-02	0.57	1978-10-31
1978-07-02	0.57	1978-07-31
1978-04-03	0.57	1978-04-30
1978-01-03	0.57	1978-01-31
1977-10-02	0.55	1977-10-31
1977-06-30	0.55	1977-07-31
1977-04-03	0.55	1977-05-01

公司名稱	戴纳基
行業分類	电力
業務描述	Dyne Therapeutics, Inc. engages in developing innovative life-transforming therapies for genetically driven muscle diseases. It develops a broad portfolio of therapeutics for muscle diseases, including lead programs in myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral muscular dystroph. The company was founded by Jason P. Rhodes and Romesh R. Subramanian on December 1, 2017 and is headquartered in Waltham, MA.

戴納基 DYN 深 滬

13.42

個股概要

財務分析

公司資料

相關新聞

分紅派息

相關新聞

公司簡介

戴納基 DYN 深滬